Meanwhile, in cholera developments, the Africa CDC reports sharp rises in illnesses in Chad and the Republic of Congo.
The test the US Centers for Disease Control and Prevention uses to identify clade I mpox cases is 'most likely not reliable' for detection of the substrain identified in the study, the authors say.
Another mpox study today showed that dose-sparing vaccine administration of the Jynneos vaccine appeared to have worked.
Receive the latest infectious disease information.
Meanwhile, Africa CDC extends its continental emergency declaration based on fragile progress, concerns about deaths, and the need to mobilize more resources.
Meanwhile, the US authorized the transfer of 219,000 vaccine doses, and the DR Congo deployed vaccine doses from Japan.
Cases and deaths have already outpaced totals for 2024, and new outbreaks have emerged in Gambia, Cameroon, and Mozambique.
The initiative is designed to accelerate testing, sequencing, capacity building, and local manufacturing for mpox and other priority pathogens.
Health officials facing depleted vaccine supplies are also tracking upticks in Nigeria, Liberia, Kenya, and Ghana, as well as in Togo and Mozambique.
The cases were reported in northern Mozambique near the Tanzanian border.
Despite declines in 2 high-burden countries, cases are rising in Burundi, Uganda, Ghana, Kenya, Liberia, and Guinea.
Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or breastfeeding women.
Though the surge in Sierra Leone has received much of the attention, cases are also rising in two other countries in West Africa: Ghana and Liberia.
Twenty five countries have reported outbreaks, including newly affected Sierra Leone where infections are surging.
